<DOC>
	<DOCNO>NCT00723658</DOCNO>
	<brief_summary>RATIONALE : Sometimes cancer may need treatment progress . In case , observation may sufficient . Giving combination chemotherapy together bortezomib , thalidomide , rituximab autologous peripheral stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , G-CSF , help stem cell move bone marrow blood collect store . More chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This observational phase II trial study well give combination chemotherapy together bortezomib , thalidomide , rituximab follow two autologous peripheral blood stem cell transplant work treat patient Waldenstrom macroglobulinemia .</brief_summary>
	<brief_title>S0629 , Observation Combination Chemotherapy , Bortezomib , Thalidomide , Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants Treating Patients With Waldenstrom Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess progression-free overall survival patient symptomatic Waldenstrom macroglobulinemia treat bortezomib , dexamethasone , thalidomide , cisplatin , doxorubicin hydrochloride , cyclophosphamide , etoposide ( VDT-PACE ) combination rituximab , follow single tandem autologous peripheral blood stem cell transplantation maintenance therapy . - To assess confirm unconfirmed response patient treat regimen . Secondary - To evaluate feasibility toxicity regimen patient . - To correlate time symptom development overall survival standard prognostic factor cytopenias . - To examine natural history Waldenstrom macroglobulinemia . - To identify , preliminary fashion , biological correlate may relate progression symptomatic disease . OUTLINE : This multicenter study . Patients asymptomatic disease study entry proceed directly observation . Patients symptomatic disease study entry proceed directly induction therapy . - Observation : Patients asymptomatic disease undergo observation monthly 3 month every 3 month 3 year . Patients develop symptomatic disease proceed induction therapy within 28 day onset disease symptom . Patients continue asymptomatic disease 3 year observation remove study . - Induction therapy : Patients receive oral dexamethasone oral thalidomide day 1-4 ; cisplatin IV , doxorubicin hydrochloride IV , cyclophosphamide IV , etoposide IV continuously day 1-4 ; bortezomib IV day 1 , 4 , 8 , 11 ; rituximab IV day 1 , 8 , 15 . Treatment repeat every 6-8 week 2 course absence disease progression unacceptable toxicity . - Peripheral blood stem cell ( PBSC ) collection : Patients receive filgrastim ( G-CSF ) IV begin day 9 course 1 induction therapy continue WBC count adequate apheresis . Patients also receive G-CSF IV begin day 6 course 2 induction therapy continue apheresis complete . - First autologous PBSC transplantation* : Beginning approximately 4-6 week completion induction therapy , patient receive condition therapy comprise high-dose melphalan IV bortezomib IV day -4 -1 . Patients undergo autologous PBSC transplantation day 0 NOTE : *Patients receive single transplant ( medical , insurance , reason ) receive melphalan bortezomib , receive condition carmustine , etoposide , cytarabine , melphalan ( BEAM ) proceed Maintenance Therapy . - Second autologous PBSC transplantation : Beginning approximately 56-90 day first transplant , patient receive condition therapy comprise carmustine IV 2 hour day -5 ; etoposide IV 1 hour cytarabine IV 1 hour day -5 -2 ; melphalan IV day -1 . Patients undergo autologous PBSC transplantation day 0 . - Maintenance therapy : Beginning platelet count recover , patient receive bortezomib IV day 1 , 4 , 8 , 11 rituximab IV 2 hour day 11 . Treatment repeat every 3 month 2 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Waldenstrom macroglobulinemia ( WM ) Measurable disease determine IgM protein quantification Must register treatment portion study within 28 day experience diseaserelated symptoms* AND must present ≥ 1 follow diseaserelated symptom : Hemoglobin ≤ 11 g/dL Platelet count ≤ 100,000/mm³ Marked tumor mass , define lymphadenopathy &gt; 2 cm , palpable hepatomegaly , splenomegaly , significant marrow involvement ( &gt; 50 % ) Serum albumin &lt; 2.5 g/dL Persistently elevate beta2microglobulin &gt; 3.0 mg/L absence renal impairment active infection Presence B symptom ( i.e. , fever , night sweat , weight loss &gt; 10 % baseline ) Appearance new worsen neuropathy manifest numbness tingle pain Symptomatic cryoglobulinemia ( i.e. , Raynaud phenomenon , skin ulcer , cold urticaria , skin necrosis ) Symptoms hyperviscosity , measure viscosity &gt; 4 cp ( i.e. , new headache , vertigo , ataxia , dizziness without evident cause change funduscopic exam , include retinal vein engorgement , hemorrhage , exudate ) NOTE : *Appearance symptom cause WM obvious cause trigger treatment initiation . Symptoms need persist specified time frame . PATIENT CHARACTERISTICS : Zubrod performance status 02 ( Zubrod performance status 3 allow provide base solely morbidity due WM ) ANC &gt; 1,500/mm³ ( unless mark cytopenia explain marked marrow involvement autoimmune myelosuppression ) Serum creatinine &lt; 3 mg/dL Creatinine clearance &gt; 30 mL/min SGOT/SGPT &lt; 2 time upper limit normal Direct bilirubin &lt; 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception accord System Thalidomide Education Prescribing Safety ( S.T.E.P.S.® ) program Ejection fraction ≥ 50 % ECHO MUGA scan Patients evidence amyloidosis ( i.e. , periorbital perforation , proteinuria attributable BenceJones protein , unexplained arrhythmia , increase liver function test , peripheral neuropathy , carpal tunnel syndrome , and/or macroglossia ) must ECHO , rather MUGA , perform evaluate cardiac amyloidosis ( septal thickness , diastolic dysfunction , granular sparkling , lowvoltage QRS complex ) No myocardial infarction within past 6 month No unstable angina No difficulttocontrol congestive heart failure cardiac arrhythmia No uncontrolled hypertension No peripheral neuropathy ≥ grade 2 No history multiinfarced dementia multiple stroke No known hypersensitivity boron mannitol No hepatitis B C positivity No HIV positivity No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : At least 28 day since prior chemotherapy and/or radiotherapy recover No prior bortezomib No concurrent glucocorticoid unless use control autoimmune disease associate WM Concurrent participation Myeloma Specimen Repository study allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Waldenström macroglobulinemia</keyword>
</DOC>